Årsredovisning 2025

Fulltext

===== SIDA 1 =====

24 February 2026 
Annual Financial Report 
  
AstraZeneca PLC (the Company) announced today the publication of its Annual Report and Form 20 -
F Information 2025 (the Annual Report). 
  
A copy of the Annual Report will be submitted to the National Storage Mechanism and will shortly be 
available for inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism. 
  
The Annual Report is also available on the Company's website www.astrazeneca.com. 
  
The Annual Report will be dispatched to shareholders in due course. 
  
The Company's Annual General Meeting (AGM) will take place on 9 April 2026. The Notice of AGM and 
Shareholders' Circular will be published and distributed to shareholders in due course.  
  
EXPLANATORY NOTE 
For the purposes of complying with the Disclosure and Transparency Rules, the Annual Report being 
submitted to the National Storage Mechanism contains the following regulated information in unedited 
form: 
  
-     the principal risks and uncertainties facing the Company; 
-     the Directors' responsibility statement made in respect of the Financial Statements and 
Directors' Report contained in the Annual Report; and 
-     a statement regarding related party transactions. 
  
AstraZeneca 
AstraZeneca (LSE/STO/NYSE: AZN) is a global, science-led biopharmaceutical company that focuses 
on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare 
Diseases, and BioPharmaceuticals, including Cardiovascular, Ren al & Metabolism, and Respiratory & 
Immunology. Based in Cambridge, UK, AstraZeneca's innovative medicines are sold in more than 125 
countries and used by millions of patients worldwide. Please visit  astrazeneca.com and follow the 
Company on Social Media @AstraZeneca. 
  
  
Contacts 
For details on how to contact the Investor Relations Team, please click  here. For Media contacts, 
click here. 
  
  
  
  
Matthew Bowden 
Company Secretary 
AstraZeneca PLC 
  
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved 
by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. 
Terms and conditions relating to the use and distribution  of this information may apply. For further 
information, please contact rns@lseg.com or visit www.rns.com.